Isocitrate Dehydrogenase mutations, IDH1, and IDH2 have been found in gliomas8,9, and classifying gliomas based on their molecular profiling of IDH status (mutated vs. wild-type) creates clinically distinct groups. This evidence concerns the gene IDH2 and glioma.